An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and AS
← catalyst calendarSponsored by Yuhan Corporation (industry) · 000100.KS — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,000estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-01-26 | actual | When the study began enrolling |
| Primary completion | 2025-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-05-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Rheumatoid Arthritis
- Ankylosing Spondylitis
Primary outcome
what the primary-completion date above is the date OFChanges in quality of life (EQ-5D-5L) scores at 52 weeks from baseline in patients with RA and AS
measured 52weeks
Permalink · 000100.KS's whole pipeline · Catalyst calendar · Every registered study · What changed